tldrdailynews.com logo

"FDA Approves New Nonsteroidal Treatment Agamree for Duchenne Muscular Dystrophy"

1 min read
Source: FDA.gov
"FDA Approves New Nonsteroidal Treatment Agamree for Duchenne Muscular Dystrophy"
Photo: FDA.gov
TL;DR Summary

The FDA has approved Duvyzat (givinostat) as the first nonsteroidal medication to treat Duchenne Muscular Dystrophy (DMD) in patients aged six and older, regardless of genetic mutation. Duvyzat, an oral histone deacetylase (HDAC) inhibitor, aims to reduce inflammation and muscle loss. Its efficacy was demonstrated in a phase 3 study, showing significant improvement in muscle function and physical ability compared to placebo. Common side effects include diarrhea, abdominal pain, and decreased platelets, with dosage adjustments required based on individual factors.

Topics:business#duchenne-muscular-dystrophy#duvyzat#fda#health#italfarmaco-spa#nonsteroidal-treatment
Share this article
  1. FDA Approves Nonsteroidal Treatment for Duchenne Muscular Dystrophy  FDA.gov
  2. Muscular Dystrophy Association’s Funding of Foundational Research Leads to New FDA Approved Treatment Duvyzat (givinostat) for Duchenne Muscular Dystrophy  Muscular Dystrophy Association
  3. Promising Phase 3 Data on DMD Hopeful Givinostat  Medscape
  4. Givinostat Receives Full FDA Approval for Duchenne Muscular Dystrophy  AJMC.com Managed Markets Network
  5. Agamree, next-gen DMD steroid, now available to patients in US  Muscular Dystrophy News

Reading Insights

Total Reads

0

Unique Readers

13

Time Saved

3 min

vs 4 min read

Condensed

88%

643 → 80 words

Want the full story? Read the original article

Read on FDA.gov